Cheryl Klaiman
Cheryl Klaiman is a Professor in the Division of Autism and Related Disorders within the Department of Pediatrics at Emory University School of Medicine and Director of Clinical Research Operations at the Marcus Autism Center. She was the director of our NIH Autism Center of Excellence Clinical Assessment Core and she is responsible for clinical characterization of individuals enrolled in the various research studies, contributing to best estimate diagnoses and training other staff psychologists, post-doctoral fellows and psychology interns as well as research assistants on diagnostic and other assessment tools.
Cheryl Klaiman has been working in the field of autism spectrum disorders since 1993, graduating with her PhD from McGill University in 2003. She completed her pre- and post-doctoral internship at the Yale Child Study Center. She was an Associate Research Scientist at Yale for 6 years prior working at the Children’s Health Council where she was the Director of the Autism and Developmental Disabilities multidisciplinary team.
Warren Jones
Dr. Jones completed his doctorate in neuroscience at Yale University. His research focuses on developing objective digital biomarkers for early identification and assessment of autism, to reduce the age of diagnosis and to provide objective measurements of treatment progress.
Dr. Jones is also the co-founder, together with Dr. Ami Klin, of EarliPoint Health, a company that translates laboratory science in autism into actionable clinical tools. In 2023, the EarliPoint Assessment for Autism received FDA clearance as the first objective tool to aid in the diagnosis and assessment of autism in children 16-30 months of age. In 2026, EarliPoint received expanded FDA clearance for use in diagnosis and assessment from 16 months until age 8 years.
Ami Klin
Ami Klin, PhD, is the Georgia Research Alliance Eminent Scholar Professor, the Bernie Marcus Distinguished Chair in Autism, and Chief of the Division of Autism and Developmental Health at Emory University School of Medicine, and Director of the Marcus Autism Center, Children’s Healthcare of Atlanta. He obtained his PhD from the University of London, and completed clinical and research post-doctoral fellowships at the Yale Child Study Center. He directed the Autism Program at the Yale Child Study Center, Yale University School of Medicine until 2010, where he was the Harris Professor of Child Psychology & Psychiatry.
Dr. Klin’s primary research activities focus on social mind and social brain, and on developmental aspects of autism from infancy through adulthood. These studies include novel techniques such as the eye-tracking laboratories co-directed with Warren Jones, which allow researchers to see the world through the eyes of individuals with autism. These techniques led to the clinical validation of EarliPoint, a biomarker-based objective and quantitative tool for the diagnosis and assessment of young children with autism cleared by the FDA for broad clinical implementation since 2023. Dr. Klin is the author of over 250 scientific publications in the field of autism and related conditions.
Vince Calhoun
Dr. Vince Calhoun is founding director of the tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS) and a Georgia Research Alliance eminent scholar in brain health and image analysis where he holds appointments at Georgia State University, Georgia Institute of Technology and Emory University. His work includes the development of flexible methods to analyze functional magnetic resonance imaging data such as independent component analysis (ICA), deep learning for neuroimaging, data fusion of multimodal imaging and genetics data, neuroinformatics tools, and the identification of brain-based biomarkers of brain health and disorder.
Mindy Scheithauer
Dr. Mindy Scheithauer is an Associate Professor at Emory University and Program Manager for outpatient services at the Marcus Autism Center, where she oversees clinical programs for children with complex behavioral needs, with a heavy focus on caregiver-mediated intervention models. Her work focuses on the assessment and treatment of severe and challenging behaviors, including elopement, aggression, self-injury, and pica. Her research is focused on behavioral assessments and treatments, toileting interventions, and the use of wearable devices to better understand and support individuals with complex behavior. Much of her clinical and research work focuses on individuals with autism and intellectual disabilities who require extensive support. The overarching goal of her research is to improve safety, independence, and quality of life for autistic individuals and their families.
Jennifer Mulle
Dr. Jennifer Mulle earned her MHS in Genetic Epidemiology and her PhD in Human Genetics from Johns Hopkins. She has been engaged in studying the contribution of common and rare genetic variation to neurodevelopmental and psychiatric illness throughout her career. The mission of her research program is to understand the phenotypic spectrum, molecular mechanism, and natural history of 3q29 deletion and 3q29 duplication syndromes.
Nathan Call
Nathan Call, PhD, BCBA-D, received his doctorate in school psychology from the University of Iowa in 2003. He has been at Marcus Autism Center since 2006, where he has held many positions as a clinician and leader of clinical programs. He is a Professor of Pediatrics and Associate Chief of the Division of Autism in the Emory University School of Medicine. His research agenda focuses on the assessment and treatment of severe forms of dangerous and destructive behavior in individuals with significant support needs, with a particular emphasis on increasing access to evidence-based practices. He has served as Principal Investigator on several federally funded randomized clinical trials of behavioral interventions targeting dangerous behavior, such as elopement, and other behavior that can negatively affect outcomes for neurodiverse individuals, such as encopresis.